US FDA grants adagrasib Breakthrough Therapy Designation for advanced non-small cell lung cancer harbouring the KRAS G12C mutation

Adagrasib is an oral small-molecule inhibitor of KRAS G12C. The designation is supported by preliminary results from the Phase 1/2 KRYSTAL-01 trial in patients with advanced NSCLC, whose cancer had progressed following prior treatment with immunotherapy and/or chemotherapy.

Source:

Biospace Inc.